MicroRNA-122 acts as tumor suppressor by targeting TRIM29 and blocking the activity of PI3K/AKT signaling in nasopharyngeal carcinoma in vitro

YAN YANG1, QING LI2 and LILI GUO3

1Clinical Laboratory, South Region of Jingmen No. 1 People's Hospital; 2Clinical Laboratory, North Region of Jingmen No. 1 People's Hospital; 3Clinical Laboratory, Jingmen No. 2 People's Hospital, Jingmen, Hubei 448000, P.R. China

Received July 31, 2017; Accepted January 25, 2018

DOI: 10.3892/mmr.2018.8894

Abstract. Nasopharyngeal carcinoma (NPC) is endemic in the southern provinces of China and Southeast Asia. It has been reported that microRNA-122 (miR-122) and tripartite motif-containing protein 29 (TRIM29) serve important roles in many types of tumor. The present study aimed to evaluate the expression of miR-122 and TRIM29, and their clinical significance in NPC, and to examine the associated molecular mechanisms. It was observed that low expression of miR-122 and high expression of TRIM29 led to a low overall survival rate in patients with NPC, which was associated with tumor-node-metastasis (TNM) stage and distant metastasis of NPC. Low expression of miR-122 was correlated reciprocally with high expression of TRIM29 in NPC tissues, and the two were aggravated by radiation treatment in NPC cell lines. Through Cell Counting kit-8 and Transwell assays, miR-122 was demonstrated to be able to inhibit the proliferation, migration and invasion of NPC cells. Through reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analyses, the expression of metastasis-associated genes, including E-cadherin, metastatic tumor antigen 1, matrix metalloproteinase-2 and metalloproteinase inhibitor 2 were demonstrated to be regulated by miR-122 in NPC cells. Additionally, through a luciferase assay, RT-qPCR and western blot analysis, it was demonstrated that TRIM29 may be a direct target of miR-122. In addition, it was noted that miR-122 decreased the expression of phosphorylated (p) phosphatidylinositol 3-kinase (PI3K) and p-RAC-α serine/threonine-protein kinase (AKT). Collectively, the results of the present study demonstrated that miR-122 may exert its tumor suppressive role by targeting TRIM29 and inhibiting the activity of PI3K/AKT signaling. It was indicated that miR-122 and TRIM29 may be developed as biomarkers of NPC, and possible molecular targets for the prevention of metastasis in patients with NPC.

Introduction

Nasopharyngeal carcinoma (NPC) frequently occurs in the nasopharynx pharyngeal fossa and the anterior wall, which originates from the nasopharyngeal mucosal epithelium (1). NPC is endemic in the southern provinces of China and Southeast Asia (2). Due to the small size of the lesion and the nonspecific symptoms in the early stages of NPC, there is a risk of misdiagnosis and eventual distant metastasis. Radiation therapy is the primary treatment for NPC at present (3). Nevertheless, distant metastasis is a frequent cause of treatment failure in patients with NPC following radiotherapy (4), and accounts in a large part for the mortality rate of this type of cancer. In addition, dissemination to distant organs and invasion of tumor cells may be facilitated by epithelial-mesenchymal transition (EMT), which facilitates cytoskeletal transfer into a more migratory state (5). A decrease in E-cadherin expression is a hallmark event in EMT (6). Therefore, there is a need to develop novel strategies for metastasis prevention and to investigate the underlying mechanisms in NPC.

MicroRNAs (miRNAs/miRs), as single-stranded, non-coding small molecule RNAs, have been implicated in various biological progresses, including the development and progression of tumors, and are widely distributed in viruses, plants and higher mammals (7-9). miRNAs bind to the 3′-untranslated region (UTR) of target mRNAs, thereby regulating the expression of target genes (10). miR-122 is dysregulated in a number of types of cancer (10-12). The tripartite motif-containing protein (TRIM) family contains N-terminal RING finger, B-box and coiled-coil domains (13). It has been reported that certain members of the TRIM family participate in multiple physiological events, including cell cycle regulation, signal transduction and oncogenic processes (14). TRIM29, as a member of the TRIM family, serves important...
roles in many tumors (15,16). Furthermore, it has been reported that TRIM29 is involved in radiodresistance in pancreatic cancer (17). An abnormal activated state of phosphatidylinositol 3-kinase (PI3K)/RAC-α serine/threonine-protein kinase (AKT) is common in a variety of types of cancer (18-20). In addition, it has been reported that the abnormal activation of PI3K/AKT signaling by TRIM29 may promote the progression of thyroid carcinoma (21). Accordingly, it may be speculated that miR-122, TRIM29 and PI3K/AKT may have an unknown association with the progression of NPC.

Therefore, the present study assessed the expression of miR-122 and TRIM29 and their clinical significance in patients with NPC. Furthermore, the potential functions of miR-122 and possible associations with TRIM29 were examined in NPC cells. The associated molecular mechanisms were additionally investigated. The results revealed that miR-122 may exert its tumor suppressive role by targeting TRIM29 and inhibiting PI3K/AKT signaling activity.

Materials and methods

Tissue specimens. The samples were collected from 30 patients with NPC who received standard treatment between June 2014 and August 2015 in Jing Men No. 1 People's Hospital. No patient had a history of cancer and other coexisting tumor. The adjacent tissues were collected at a site 5 cm from the tumor locus. Written informed consent was obtained from all patients prior to enrolling in the study. The clinical characteristics of the patients are presented in Tables I-III. The protocols associated with the use of patient tissues were approved by the ethics committee of Jing Men No. 1 People's Hospital (Jingmen, China).

Cell culture and treatment. Human NPC cell lines 5-8F (CA-89) and 6-10B (CA-91) were obtained from Changsha Axybio Biotechnology Co., Ltd. (Changsha, China). The cells were maintained in RPMI-1640 medium ( Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) and 50 µg/ml streptomycin in a 37°C incubator containing 5% CO2. An 8 MV linear accelerator (Elekta Instrument AB, Stockholm, Sweden) was used for one-time exposure at room temperature with the source-skin distance of 100 cm. The irradiation dose was 3 Gy and the dose rate may vary from 0.5 to 1 Gy/min. The control group was not irradiated.

The miR-122 mimics (5'-UGGAGUGUGACAAUGGUGUUUG-3') and corresponding negative control (5'-UCCGAA CGUGUCACGUTT-3') were purchased from Shanghai GenePharma Co., Ltd (Shanghai, China). Cells (1x104/well) were seeded into 6-well plates. A total of 12 h post-incubation at 37°C, either miR-122 mimics (75 nM) or corresponding negative control (75 nM) were transfected using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.), followed by the manufacturer’s protocol. Following a further 24 h of incubation at 37°C, the cells were subjected to subsequent analysis.

Cell proliferation detection. The survival rate of transfected cells was determined using a Cell Counting kit-8 (CCK-8) assay (MedChemExpress, Monmouth Junction, NJ, USA). The cells (2x103) were incubated in 96-well plates (100 μl/well). A total of 10 μl CCK-8 solution was added and incubated for 4 h at 37°C. The absorbance was measured with microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 450 nm.

Cell migration and invasion assays. Transwell assays were performed to observe the migratory and invasive abilities of transfected cells. The cells (1x105) in serum-free medium were placed onto the upper Matrigel-coated insert (for the invasion assay) or insert without Matrigel (for the migration assay) of Transwell chambers (Corning Incorporated, Corning, NY, USA). Complete medium was added to the lower chamber. A 24-well plate was used to hold the Transwell inserts. Following 16 h, the cells that stayed on the upper surface were removed, and the cells that had migrated through the pores were collected. Another group was maintained at 37°C for 24 h to allow the cells to invade through the Matrigel into the bottom membrane. Subsequent to fixing with 4% paraformaldehyde for 15 min at room temperature, the collected cells were stained with crystal violet (0.1%) for 20 min at room temperature and quantified using a light microscope (magnification, x100; Nikon Corporation, Tokyo, Japan).

Luciferase assay. Bioinformatics analysis was performed using TargetScan (http://www.targetscan.org/vert_71/) and microRNA.org (http://www.microrna.org/). The wild type (wt) TRIM29-3’UTR reporter plasmid was purchased from Shanghai Axybio Biotechnology Co., Ltd. The mutant type (mut) TRIM29 3’UTR plasmid was generated using a site-directed mutagenesis kit (Takara Bio, Inc., Otsu, Japan) by mutating the site of the target region of miR-122 (CACACUCC to GAGAGAGT), based on the wt TRIM29-3’UTR reporter plasmid. The cells were seeded at a density of 5x103/well into a 6-well plate. After 24 h, the cells were co-transfected with miR-122 mimics or miR-negative control, wt/mut TRIM29 3’UTR reporter plasmid and a Renilla luciferase pRL-TK vector (Promega Corporation, Madison, WI, USA) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). At 48 h, according to the manufacturer’s protocol, a dual-luciferase assay system (Promega Corporation) was employed to measure the luciferase activity. The luciferase activity was normalized to Renilla luciferase activity.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used for the extraction of total RNA and miRNA. The cDNA was synthesized using total RNA, oligo(dT)18 primers (Takara Bio, Inc.) and M-MLV reverse transcriptase (Promega Corporation). The temperature protocol used for RT was as follows: 25°C for 10 min, 42°C for 50 min and 70°C for 10 min. A TaqMan miRNA reverse transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) and a TaqMan human miRNA assay kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) was used for the amplification and quantification of miR-122, respectively. U6 was adopted as the internal control for miR-122. qPCR was performed with Fast SYBR Green Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) on the ABI StepOne Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions used were as follows: 95°C for 10 min; followed by 40 cycles at 95°C for 15 sec and 60°C
for 60 sec; and a final extension step at 72°C for 7 min. Primers for miR-122 were purchased from Changsha Axybio Biotechnology Co., Ltd. The primer sequences used were as follows: miR-122 forward, 5’-GCC GTG GAG TGT GAT-3’; and reverse, 5’-GTG CAG GGT CCG AGG TCA ATG G-3’. The other primer sequences were as follows: U6 forward, 5’ -CTC GCT TCG AGC ACA-3’ and reverse, 5’-AAC GCT TCA CGA ATT TGC GT-3’; TRIM29 forward 5’-ACT CCT TTC CTG CCT TGT GA-3’ and reverse, 5’-GAG AGG CAG GCT GAT ACC AT-3’; E-cadherin forward 5’ -TCA CAT CCT ACA CTG CCC AG-3’ and reverse, 5’-AGT GTC CCT GTT CCA GTA GC-3’; metastatic tumor antigen 1 (MTA1) forward, 5’ -ACA GAC AAG CAG ATC GAC CA-3’ and reverse, 5’-GGC CTT GGA GAT GTC GTA GA-3’; matrix metalloproteinase-2 (MMP-2) forward, 5’-CGG TGC CCA AGA ATA GAT GC-3’ and reverse, 5’-AGA CAG TCT CCA TTG GCT CC-3’; metalloproteinase inhibitor (TIMP2) forward, 5’-TGT GTT CCC TCAG TGT GGTT-3’ and reverse, 5’-TTC GGT TTC ATT GCG TGT GT-3’. The 2ΔΔCq method was used to analysis the relative expression level of target factors (22).

Western blot analysis. The extraction and separation of proteins was performed using radioimmunoprecipitation assay lysis buffer (Thermo Fisher Scientific, Inc.). Protein concentration was determined using a bicinchoninic acid protein quantification kit (Thermo Fisher Scientific, Inc.). Protein samples were then separated on 10% SDS-PAGE gels (20 µg/lane). The proteins were transferred onto polyvinylidene fluoride membranes. The blots were blocked with 5% bovine serum albumin (Beijing Solarbio Science & Technology, Co., Ltd., Beijing, China) at room temperature for 2 h and then incubated with primary antibodies at 4°C overnight. The next day, the blots were maintained with horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h. The blots were determined with enhanced chemiluminescence reagents (Thermo Fisher Scientific, Inc.). Densitometry was performed using Quantity One software version 4.6.9 (Bio-Rad Laboratories, Inc.).

Table I. Correlation analysis between clinical features and the expression of miR-122 in patients with NPC.

| Characteristics | No. patients | Low group | High group | P-value |
|-----------------|--------------|-----------|------------|---------|
| Age, years      |              |           |            |         |
| ≤45             | 12           | 5         | 7          | 0.358   |
| >45             | 18           | 10        | 8          |         |
| Sex             |              |           |            | 0.961   |
| Male            | 17           | 9         | 8          |         |
| Female          | 13           | 7         | 6          |         |
| TNM stage       |              |           |            | 0.002a  |
| I+II            | 10           | 1         | 9          |         |
| III+IV          | 20           | 14        | 6          |         |
| Distant metastasis |          |           |            | <0.01a  |
| No              | 13           | 1         | 12         |         |
| Yes             | 17           | 14        | 3          |         |

Table II. Correlation analysis between clinical features and the expression of TRIM29 in patients with NPC.

| Characteristics | No. patients | Low group | High group | P-value |
|-----------------|--------------|-----------|------------|---------|
| Age, years      |              |           |            |         |
| ≤45             | 12           | 5         | 7          | 0.713   |
| >45             | 18           | 10        | 8          |         |
| Sex             |              |           |            | 0.409   |
| Male            | 22           | 12        | 10         |         |
| Female          | 8            | 3         | 5          |         |
| TNM stage       |              |           |            | 0.002a  |
| I+II            | 10           | 9         | 1          |         |
| III+IV          | 20           | 14        | 6          |         |
| Distant metastasis |          |           |            | 0.010a  |
| No              | 13           | 10        | 3          |         |
| Yes             | 17           | 5         | 12         |         |

Table III. Correlation analysis of expression between miR-122 and TRIM29.

| Characteristics | No. patients | Low group | High group | P-value |
|-----------------|--------------|-----------|------------|---------|
| miR-122         |              |           |            |         |
| -               | 4            | 9         |            | -0.522  |
| +               | 14           | 3         |            |         |

Table IV. Correlation analysis between clinical features and the expression of TRIM29 in patients with NPC.

| Characteristics | No. patients | Low group | High group | P-value |
|-----------------|--------------|-----------|------------|---------|
| Age, years      |              |           |            |         |
| ≤45             | 12           | 5         | 7          | 0.713   |
| >45             | 18           | 10        | 8          |         |
| Sex             |              |           |            | 0.409   |
| Male            | 22           | 12        | 10         |         |
| Female          | 8            | 3         | 5          |         |
| TNM stage       |              |           |            | 0.002a  |
| I+II            | 10           | 9         | 1          |         |
| III+IV          | 20           | 14        | 6          |         |
| Distant metastasis |          |           |            | 0.010a  |
| No              | 13           | 10        | 3          |         |
| Yes             | 17           | 5         | 12         |         |

TCGGCGACACA-3’ and reverse, 5’-AACGCTTACAGAATT TGCGT-3’; TRIM29 forward 5’-ACTCTTTTCTGTGCCTGT GA-3’ and reverse, 5’-GAGAGGCGAGCTGATACC-3’; E-cadherin forward 5’-TCACATCCACACTGCCCAG-3’ and reverse, 5’-AGTGCTCTGGTGATGCAG-3’; metastatic tumor antigen 1 (MTA1) forward, 5’-ACAGACAGCGATCGACCA-3’ and reverse, 5’-GGCCTTGAGATGTCGTA GA-3’; matrix metalloproteinase-2 (MMP-2) forward, 5’-CGG TGCCCAAGATAGTGC-3’ and reverse, 5’-ACAGAC TCCATTGCGTCCC-3’; metalloproteinase inhibitor (TIMP2) forward, 5’-TGCTTTCCATAGTGTTT-3’ and reverse, 5’-TCCGGTTTTTGCGTGTTG-3’.

Western blot analysis. The extraction and separation of proteins was performed using radioimmunoprecipitation assay lysis buffer (Thermo Fisher Scientific, Inc.). Protein concentration was determined using a bicinchoninic acid protein quantification kit (Thermo Fisher Scientific, Inc.). Protein samples were then separated on 10% SDS-PAGE gels (20 µg/lane). The proteins were transferred onto polyvinylidene fluoride membranes. The blots were blocked with 5% bovine serum albumin (Beijing Solarbio Science & Technology, Co., Ltd., Beijing, China) at room temperature for 2 h and then incubated with primary antibodies at 4°C overnight. The next day, the blots were maintained with horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h. The blots were determined with enhanced chemiluminescence reagents (Thermo Fisher Scientific, Inc.). Densitometry was performed using Quantity One software version 4.6.9 (Bio-Rad Laboratories, Inc.).

The primary antibodies used were as follows: Anti-phosphorylated (p)‑PI3K p85 (Tyr458)/p55 (Tyr199; 1:1,000; cat. no. 4228), anti-p-AKT (Ser473; 1:2,000; cat. no. 4060), anti-PI3K Class III (1:1,000; cat. no. 3358), anti-AKT (pan; 1:1,000; cat. no. 4685; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-TRIM29 (1:1,000; cat. no. ab108627; Abcam, Cambridge, UK), anti-E-cadherin (1:1,000; cat. no. 3195), anti-MTA1 (1:1,000; cat. no. 5646; both Cell Signaling Technology, Inc.), anti-MMP-2 (1:1,000; cat. no. sc13594; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and GAPDH (1:5,000; cat. no. ab8245; Abcam). The secondary antibodies were purchased from Beijing CoWin Biotech Co., Ltd. (Beijing, China; cat. nos. Cw0102s and Cw0103s; 1:2,000).
YANG et al: miR-122 ACTS AS A TUMOR SUPPRESSOR IN NASOPHARYNGEAL CARCINOMA

Statistical analysis. Data are presented as mean ± standard deviation. All experiments were performed independently at least three times. A χ² test was used to analyze categorical variables. A two-tailed Student's t-test or one-way analysis of variance followed by Dunnett's post-hoc multiple comparison test was employed to compare the differences between groups. Kaplan-Meier analysis was used to draw the survival curves. Spearman's rank correlation analysis was used to analyze bivariate correlations. SPSS v.14.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) software was used for all the statistical analysis and graph-drawing. P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of miR-122 and TRIM29 in patients with NPC and cell lines. In order to determine the expression of miR-122 and TRIM29 in patients with NPC, RT-qPCR was performed to analyze their expression levels in cases with and without metastasis. It was demonstrated that miR-122 expression was decreased in NPC cases without metastasis (p-NPC), and more so in cases with metastasis (m-NPC). By contrast, the expression of TRIM29 was increased in p-NPC and further enhanced in m-NPC (Fig. 1A and B). Furthermore, the decreased miR-122 expression and the increased TRIM29 expression were significantly correlated with advanced TNM stage and distant metastasis (Tables I and II). According to a previous study (23), the NPC patients were divided into two groups based on the median value of miR-122 or TRIM29 expression: miR-122/TRIM29 high expression group (n=15), and miR-122/TRIM29 low expression group (n=5). The overall survival (OS) rate in the patients with low miR-122 expression was decreased compared with those in the high miR-122 group (Fig. 1C; P<0.05). However, patients with low TRIM29 expression had a higher OS rate compared with those with high TRIM29 expression (Fig. 1D; P<0.05). In addition, the expression of miR-122 and TRIM29 in patients with NPC was negatively correlated (Table III).

Subsequently, the expression of miR-122 and TRIM29 was detected in NPC cell lines, including 5-8F and 6-10B, following radiation treatment. The RT-qPCR analysis demonstrated that, in all NPC cell lines following radiation treatment, miR-122 and TRIM29 were downregulated and upregulated, respectively (Fig. 1E and F). The expression of TRIM29 was further confirmed by western blot analysis (Fig. 1G and H).
miR‑122 inhibits the proliferation, migration and invasion of NPC cells. The potential role of miR-122 and TRIM29 in the progression and metastasis of NPC was determined. The results of the present study demonstrated that the expression of miR‑122 was increased significantly in NPC cells that were transfected with miR-122 mimics (Fig. 2A). Furthermore, the cell survival rate was decreased in the miR-122 mimics group compared with the control and negative groups (Fig. 2B). The Transwell assays illustrated that the migratory and invasive abilities of NPC cells were decreased by overexpression of miR-122 (Fig. 2C-F).

miR-122 regulates the expression of metastasis-associated genes. The expression of metastasis-associated genes in the miR-122 mimics group was assessed. MTA1 is associated with tumor metastasis (24). As presented in Fig. 3, the expression of E-cadherin and MTA1 was increased and decreased in the miR-122 mimics group, respectively. The extracellular matrix may be degraded by MMP-2 during the progression of cell invasion (25). It was noted that the expression of MMP-2 was decreased in the miR-122 mimics group compared with the control and negative control groups. Conversely, TIMP2, a suppressor of MMP-2 (26), was upregulated by the overexpression of miR-122 (Fig. 3A-C).

TRIM29 may be a direct target of miR-122. The expression of TRIM29 was inhibited at the mRNA and protein levels in the miR-122 mimics group (Fig. 4A-C). In addition, bioinformatics analysis from available databases (TargetScan and microRNA.org) indicated that TRIM29 was a possible target of miR-122 (Fig. 4D). Meanwhile, the results of the luciferase reporter assay demonstrated that the luciferase activity of the
wild-type TRIM29 3'-UTR was inhibited by the excessive expression of miR-122, whereas the luciferase activity of the mutant TRIM29 3'-UTR was not affected (Fig. 4E). To confirm this result, the luciferase activity reporter assay was performed in another NPC cell line, 5-8F. The results were consistent between the two NPC cell lines (Fig. 4F). These data indicated that TRIM29 may be a direct target of miR-122.

miR‑122 decreases the expression of p‑PI3K and p‑AKT. To further clarify the underlying molecular mechanisms, the activity of PI3K/AKT was evaluated in NPC cells transfected with miR-122. The results of the western blotting demonstrated that the expression levels of p-PI3K and p-AKT were decreased by the overexpression of miR-122 (Fig. 5).

Discussion

Recently, varieties of miRNAs have been demonstrated to be the key regulators in tumor metastatic processes (27). Previous studies have reported that miR-122 serves as a tumor suppressor and is suppressed in a number of types of cancer, including gallbladder cancer, gastric cancer, non-small-cell lung cancer and hepatocellular carcinoma (12,28,29). High expression of TRIM29 has been identified in a number of aggressive diseases, and is an important oncogenic factor in cancer (15). It has been reported that poor prognosis may be associated with dysregulated miR-122 and TRIM29 (30,31). Consistently, the results of the present study demonstrated that miR-122 and TRIM29 expression was downregulated and upregulated in NPC tissues, particularly in cases with metastasis, respectively. Furthermore, low miR-122 expression and high TRIM29 expression were significantly associated with advanced TNM stage and distant metastasis in patients with NPC. A poor patient overall survival rate was observed in the low miR-122 group and the high TRIM29 group. Additionally, a significant negative correlation between the expression of miR-122 and TRIM29 was observed in patients with NPC. It was indicated that the dysregulation of miR-122 and TRIM29 may serve as a prognostic biomarker and optional target for NPC. Distant metastasis is the primary cause of treatment failure in patients with NPC following radiation therapy (32). The prevention of metastasis in radiation therapy may be a promising strategy for the treatment of NPC. Hence, the expression of miR-122 and TRIM29 was determined in NPC cell lines following radiation treatment. As hypothesized, decreased miR-122 expression and increased TRIM29 expression was identified in NPC cell lines with radiation treatment.
Figure 4. TRIM29 may be a direct target of miR-122. (A) miR-122 decreased the expression of TRIM29 at the mRNA level. miR-122 decreased the expression of TRIM29 at the protein level, as demonstrated by (B) western blotting and (C) densitometry. (D) The potential complementary sequences of the wt TRIM29 3'UTR and mut TRIM29 3'UTR, and the miR-122 binding sequence. (E) miR-122 depressed the luciferase activity of the wt 3'-UTR of TRIM29 in 6-10B cells. (F) miR-122 depressed the luciferase activity of the wt 3'-UTR of TRIM29 in 5-8F cells. Data are presented as the mean ± standard deviation, n=3. *P<0.05 vs. control. TRIM29, tripartite motif-containing protein 29; NC, negative control; wt, wild-type; mut, mutant; UTR, untranslated region; miR, microRNA; Con, control.

Figure 5. miR-122 decreases the expression levels of p-PI3K and p-AKT. (A) Western blot analysis and (B) determination of the expression of p-PI3K. (C) Western blot analysis and (D) determination of the expression of p-AKT. Data are presented as the mean ± standard deviation, n=3. *P<0.05 vs. control. miR, microRNA; p, phosphorylated; PI3K, phosphatidylinositol 3-kinase; AKT, RAC-α serine/threonine-protein kinase; NC, negative control; Con, control.
Unlimited proliferation and metastasis are the prominent properties of malignant tumors (33). The failure of radiation therapy is primarily caused by distant metastasis. The present study further clarified the potential effect of miR-122 on the metastasis of NPC in vitro. It was observed that the overexpression of miR-122 was able to inhibit tumor progression by suppressing the viability, migration and invasion of NPC cells, which indicated the antitumor effects of miR-122. These data indicated that miR-122 acted as a tumor suppressor in NPC cells, and were supported by previous observations in multiple types of cancer (29,34,35). However, it was likely that the decrease in cell viability may also indirectly suppress the invasion and migration of NPC cells. Therefore, the effect of miR-122 on the activity and expression of metastasis-associated genes was assessed. It was revealed that the expression of metastasis-associated genes, including E-cadherin, MTA1, MMP-2 and TIMP2, was regulated by miR-122. However, due to the complexity of tumorigenesis and the intracellular signal transduction network, certain studies have claimed that the overexpression of miR-122 may be associated with poor patient prognosis in colorectal cancer (36) and renal cancer (37). In addition, the expression of TRIM29 was downregulated in NPC cells that were transfected with miR-122. Based on the above investigations, it was speculated that miR-122 may exert its role by blocking the expression of TRIM29. To verify this possibility, bioinformatics databases were searched to predict the downstream targets of miR-122. The analysis results demonstrated that possible miR-122 binding sites were located in the 3’-UTR of TRIM29. Further evidence of this was provided by the results of the luciferase reporter assay, in the 6-10B and 5-8F cell lines, in the present study. It was therefore suggested that TRIM29 may be a direct target of miR-122 and serve as an oncogene in NPC. However, the tumor suppressor role of TRIM29 has additionally been reported in certain studies (38,39). Thus, the function of TRIM29 may be context-dependent in the progression of different tumors. To illustrate the in-depth molecular mechanisms, the activity of PI3K/AKT signaling, which is dysregulated in a number of types of cancer, was detected (40). The results revealed that the phosphorylation of PI3K and AKT was decreased by miR-122. A study in thyroid cancer reported that the activation of the PI3K/AKT signaling pathway was inhibited by decreased TRIM29 expression (21). However, it remains unclear whether or not PI3K/AKT was modulated by TRIM29 in the present study and thus requires further investigation.

The results of the present study suggested a potential role of miR-122 and TRIM29 in metastatic progression following radiation therapy. However, the present study did not provide further evidence for the effect of miR-122 in the radiation treatment of NPC. However, it was necessary to undertake in vivo studies to assess the antitumor effect of miR-122 in patients with NPC following radiation therapy. These investigations implied that the antitumor effect of miR-122 in NPC was promising, although this requires validation in future studies.

In conclusion, decreased expression of miR-122 and increased expression of TRIM29 was significantly associated with poor prognosis in patients with NPC. miR-122 may exert antitumor effects through suppression of tumor proliferation, invasion and migration, and modulation of the expression and activity of metastasis-associated genes, including E-cadherin, MTA1, MMP-2 and TIMP2. Notably, miR-122 may suppress NPC progression by targeting TRIM29 and blocking the activity of PI3K/AKT signaling. Therefore, miR-122 and TRIM29 may be developed as biomarkers and possible molecular targets for the metastasis of NPC.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during the present study are included in this published article.

Authors’ contributions

LG designed the present study. QL and YY wrote the manuscript. YY and QL performed the experiments. QL performed data analysis. YY, QL and LG revised the manuscript for important intellectual content.

Ethics approval and consent to participate

Written informed consent was obtained from all patients prior to enrolling in the present study. The protocols associated with the use of patient tissues were approved by the ethics committee of Jing Men No. 1 People's Hospital (Jingmen, China).

Consent for publication

Written informed consent was obtained from all patients prior to enrolling in the present study.

Competing interests

The authors declare that they have no competing interests.

References

1. Huang DP, Ho JH, Poon YF, Chew EC, Saw D, Lui M, Li CL, Mak LS, Lai SH and Lau WH: Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer 26: 127-132, 1980.
2. Lee JH, Zhang J, Wei L and Yu SP: Neurodevelopmental implications of the general anesthesia in neonate and infants. Exp Neurol 272: 50-60, 2015.
3. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, et al: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation therapy oncology group phase II trial 0225. J Clin Oncol 27: 3684-3690, 2009.
4. Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, Tian L, Tang LL, Lin AH, Li L and Ma J: The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol 104: 331-337, 2012.
5. Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33, 2009.
6. Fri xen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Löchner D and Birchmeier W: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173-185, 1993.

7. Ambros V: MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell 113: 673-676, 2003.

8. Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789, 2010.

9. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yandamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Nat Acad Sci USA 101: 2999-3004, 2004.

10. Ying SY, Chang DC and Lin SL: The microRNA (miRNA): Overview of the RNA genes that modulate gene function. Mol Biotechnol 38: 257-268, 2008.

11. Wang N, Wang Q, Shan D, Sun X, Cao X and Wu D: Downregulation of microRNA-122 promotes proliferation, migration, and invasion of human hepatocellular carcinoma cells by activating epithelial-mesenchymal transition. Onco Targets Ther 9: 2035-2047, 2016.

12. Qin H, Sha J, Jiang C, Gao X, Qu L, Yan H, Xu T, Jiang Q and Gao H: miR-122 inhibits metastasis and epithelial-mesenchymal transition of non-small-cell lung cancer cells. Onco Targets Ther 8: 3175-3184, 2015.

13. Watanabe M and Hatakeyama S: TRIM proteins and diseases. J Biochem 161: 135-144, 2017.

14. Sato T, Takahashi H, Hatakeyama S, Igiuchi A and Ariga T: The TRIM-FLMN protein TRIM45 directly interacts with RACK1 and negatively regulates PKC-mediated signaling pathway. Oncogene 34: 1280-1291, 2015.

15. Kosaka Y, Inoue H, Ohmachi T, Yokoe T, Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol 14: 2543-2549, 2007.

16. Kanno Y, Watanabe M, Kimura T, Nonomura K, Tanaka S and Hatakeyama S: TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer. Acta Histochem 116: 708-712, 2014.

17. Wang L, Yang H, Palmbos PL, Ney G, Detzler TA, Coleman D, Lefflin J, Davis M, Zhang M, Tang W, et al: ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells. Cancer Res 74: 1778-1788, 2014.

18. Nicholson KM and Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 14: 381-395, 2002.

19. Aoki M and Fujishita T: Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol 407: 153-189, 2017.

20. Grille SJ, Bellacosa A, Upson J, Klein‑Szanto AJ, van Roy F, Eberle G, Birkedal‑Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal‑Hansen B, DeCarlo A and Engler JA: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 4: 197-250, 1993.

21. Musso O, Théret N, Campion JP, Turlin B, Milani S, Grappone C and Clément B: In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol 26: 593-605, 1997.

22. Ma L: MicroRNA and Metastasis. Adv Cancer Res 132: 165-207, 2016.

23. Ergün S, Ulaslı M, Içgi YZ, Içgi M, Kırksbės S, Borazan E, Balık A, Yumruşuş Ö, Camci C, Cakmak EA, et al: The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Mol Biol Rep 42: 497-505, 2015.

24. Wang Y, Xing QF, Liu XQ, Guo ZJ, Li CY and Sun G: MiR-122 targets VEGFC in bladder cancer to inhibit tumor growth and angiogenesis. Am J Transl Res 8: 3056-3066, 2016.

25. Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbajo M, Segersten U, Malmström PU, Palou J, Alvarez-Múgica M, Pan CC, Uhlbo EP, et al: Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol 182: 339-349, 2013.

26. Glebov OK, Rodriguez LM, Soballe P, De Noblie J, Ciat J, Nakahara K and Kirsch IR: Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15: 2253-2262, 2006.

27. Gearing FB, Sanguineti G, Tucker SL, Garzon R, Morrison WH and Peters LJ: Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of distant metastasis and survival. Radiother Oncol 43: 53-61, 1997.

28. Schram FR and Ng PKL: What is Cancer? J Crust Biol 32: 665-672, 2012.

29. Rao M, Zhu Y, Zhou Y, Cong X and Feng L: MicroRNA-122 inhibits proliferation and invasion in gastric cancer by targeting CREB1. Am J Cancer Res 7: 323-333, 2017.

30. Qiao DD, Yang J, Lei XF, Mi GL, Li SL, Li K, Xu CQ and Yang HL: Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features. Eur Rev Med Pharmacol Sci 21: 742-747, 2017.

31. Maierthaler M, Benner A, Hoffmeister M, Surowy H, Jensen L, Knobel P, Chang-Claude J, Brenner H and Burwinkel B: Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int J Cancer 140: 176-187, 2017.

32. Jungushi K, Kashiwagi Y, Ueda Y, Kitae K, Hase H, Nakata W, Gondo K, Uemura M, Nonomura N and Tsugikawa K: High miR-122 expression promotes malignant phenotypes in ccRCC by targeting occludin. Clin Cancer Res 22: 5604-5614, 2016.

33. Liu J, Welm B, Boucher KM, Ebbert MT and Bernard PS: TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer. Am J Pathol 180: 839-847, 2012.

34. Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med 46: 372-383, 2014.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.